News

It wasn't much of a surprise that investors cautiously bid up Eli Lilly stock -- and that of its GLP-1 drug making rival, Wegovy developer Novo Nordisk-- following the article's publication. Any such ...
President Donald Trump's new European tariffs could significantly increase the cost of Novo Nordisk's weight loss drug, Ozempic.